Last reviewed · How we verify
LC350189 Tablet
At a glance
| Generic name | LC350189 Tablet |
|---|---|
| Also known as | LC350189 |
| Sponsor | LG Chem |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects (PHASE2)
- Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects (EARLY_PHASE1)
- Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LC350189 Tablet CI brief — competitive landscape report
- LC350189 Tablet updates RSS · CI watch RSS
- LG Chem portfolio CI